Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy by Kim, Yang Yeol et al.
496 http://neuro.psychiatryonline.org J Neuropsychiatry Clin Neurosci 20:4, Fall 2008
LETTERS
lessness, or insomnia. An extensive
literature search revealed a prior re-
port of trifluoperazine withdrawal
symptoms like craving, irritability,
dysphoria, and inability to work.3
Below, we describe the develop-
ment of nonpsychotic withdrawal
symptoms in a patient after use of
trifluoperazine for several years.
Case Report
A 78-year-old Indian man pre-
sented to us with a moderate de-
pressive episode for 1 month. He
had two previous episodes of de-
pression which occurred 45 and 20
years ago, respectively. Both the ep-
isodes fully resolved with treat-
ment, and the patient had no resid-
ual depressive symptoms in
between the episodes. He also had
severe nicotine dependence (smoke-
less tobacco) for about 56 years,
from which he was abstinent for the
previous year.
The patient was treated with anti-
depressants for his second episode
of depression along with trifluoper-
azine, 2 mg/day. After 1 month, his
depressive symptoms resolved
completely, and he stopped taking
the antidepressants. However, he
continued taking trifluoperazine in
the same dose for the next 20 years.
He said that if he ever tried to stop
this medicine he felt very weak,
restless, dysphoric, and had diffi-
culty getting to sleep. But there was
never any depressive cognition,
guilty feeling, or other characteristic
depressive symptoms. On days
when he could not take this medi-
cine, he experienced a craving for it.
He and his family members felt that
this was not normal and he tried to
reduce the dose to 1 mg/day. Such
attempts failed when he developed
the above-mentioned symptoms the
next day, which forced him to re-
start trifluoperazine, 2 mg/day.
Symptoms resolved immediately
every time thereafter. At times he
started taking 3 mg/day, but gener-
ally he maintained a dosage of 2
mg/day.
We treated the patient with esci-
talopram, 20 mg/day, for his de-
pression and clonazepam, 1 mg/
day, for associated sleep problems
which developed during this de-
pressive episode. With this he
showed marked improvement in
depressive symptoms. He was,
however, still continuing trifluoper-
azine and was not motivated to
stop it. When we asked him to try
abstinence from trifluoperazine, he
said he was unable to do away with
it.
Discussion
Our patient fulfilled ICD-10 criteria
of a possible trifluoperazine with-
drawal syndrome. This is interest-
ing because unlike all other depen-
dence-producing substances,
trifluoperazine is a dopamine block-
ing agent and is not expected to
stimulate the mesolimbic/mesocort-
ical dopaminergic reward circuit. So
it might be due to a sensitive re-
ward circuit in our patient, as evi-
denced by his severe nicotine de-
pendence. Further research is
needed to examine the possibility of
a unique trifluoperazine with-
drawal syndrome. As trifluopera-
zine is very commonly used in de-
veloping countries like India
because of its low cost, such a find-
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Replacement Therapy in a
Patient with Progressive
Supranuclear Palsy
To the Editor: The pathogenesis of
pathological hypersexuality is still
in controversy. To our knowledge,
this is the first report of pathologi-
cal hypersexuality induced by two
different dopamine receptor ago-
nists in a single patient with pro-
gressive supranuclear palsy. In this
case, dopamine D2 receptor agon-
ism, perhaps specifically D3 recep-
tor subclass agonism, might have
played a key role in the develop-
ment of pathological hypersexuality
induced by dopamine replacement
therapy.
Case Report
An 83-year-old man with progres-
sive supranuclear palsy was being
treated with Sinemet (carbidopa/L-
dopa 25 mg/100 mg, 125 mg t.i.d.)
for 8 months. Due to nausea, Sine-
met was replaced by low dose ma-
dopar (L-dopa/benserazid 100 mg/
25 mg, 62.5 mg t.i.d.) and bromo-
criptine (2.5 mg t.i.d.). For the fol-
lowing 2 months, pathological hy-
persexuality (sexually suggestive
remarks, touching, kissing, disrob-
ing, exposing genitalia, facial flush-
ing, penile erection, public mastur-
bation) slowly developed. At this
point, his serum testosterone level
J Neuropsychiatry Clin Neurosci 20:4, Fall 2008 http://neuro.psychiatryonline.org 497
LETTERS
was normal (2.3 ng/ml), whereas
serum prolactin level was sup-
pressed to 1.3 ng/ml.
His pathological hypersexuality
completely disappeared 2 weeks af-
ter discontinuation of bromocrip-
tine. After 4 weeks, pramipexole
(0.125 mg b.i.d.), another dopamine
receptor agonist, was added instead
of bromocriptine since his motor
performance deteriorated. After 1
week of pramipexole, all the hyper-
sexual symptoms reemerged. At
this point, his serum prolactin level
was 2.2 ng/ml.
His pathological hypersexuality
completely disappeared again just
by discontinuing pramipexole. Then
we titrated madopar up to 125 mg
t.i.d. instead of adding other dopa-
mine receptor agonist. After 3
weeks, his motor performance im-
proved with partial reemergence of
hypersexual symptoms (penile erec-
tion, facial flushing, sexually sug-
gestive remarks, touching). How-
ever, the severity of the reemerged
symptoms was much more tolera-
ble than those induced by dopa-
mine receptor agonist. At this point,
his serum prolactin level was not
suppressed (13.3 ng/ml).
Comments
This case confirmed an earlier ob-
servation1 through rechallenging
two different kinds of dopamine re-
ceptor agonists alternatively in a
single patient, and illustrated sev-
eral characteristics of dopamine re-
placement therapy-induced patho-
logical hypersexuality.
First, dopamine receptor agonists
may be more likely to induce
pathological hypersexuality than L-
dopa since pathological hypersexu-
ality induced by combination ther-
apy of either bromocriptine or
pramipexole with L-dopa was much




persexuality may be mediated by
D2 receptor agonism since prami-
pexole has no affinity for D1 recep-
tor classes.2
Third, dopamine receptor ago-
nist-induced pathological hypersex-
uality may perhaps be mediated by
the excessive stimulation of the D3
receptor subclass since pramipexole
binds preferentially to D3 receptors
with high affinity.2
Fourth, the difference in the risk
of pathological hypersexuality be-
tween dopamine receptor agonists
and L-dopa may be attributed to
their differential suppression of
prolactin secretion since serum pro-
lactin was abruptly suppressed
when bromocriptine or pramipexole
was added to L-dopa. Inhibitory ef-
fect of dopamine receptor agonists
on prolactin secretion was sug-
gested as a main pathogenic mecha-
nism of hypersexuality.3
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To the Editor: Nicotine is possibly
one of the most prevalent depen-
dence-producing drugs because of
the central nicotinic-cholinergic, do-
paminergic, serotonergic, and gaba-
minergic pathways with which it
has been associated.1 Nicotine-de-
pendent behavior may conceivably
be reinforced by the drug’s focus
and memory enhancing properties,2
as well as antidepressant,3 anxio-
lytic,4 and appetite-suppressing
properties.5 Nicotine is a unique
paradigm in that it suppresses ap-
petite and stabilizes mood. Nicotine
withdrawal leads to the emergence
of craving in dependent individ-
uals, which can include impaired
memory6 and concentration, de-
pressed mood, anxiety, and in-
creased appetite.7
Although less clearly understood
than nicotine withdrawal, food-
seeking behavior also is believed to
involve an array of neuropsychiat-
ric reward pathways. Nicotinic-cho-
linergic,8 dopaminergic,9 serotoner-
gic, and GABA-ergic10 reward
systems are among the likely candi-
dates that motivate us to eat. Food-
seeking has been associated with
depression, stress, and emotional
discomfort,11 and food tasting alone
can stabilize mood.12
Varenicline is a new treatment for
nicotine dependence and a nico-
tinic-cholinergic receptor partial
agonist that behaves like nicotine.
We report a case of varenicline-as-
sociated appetite suppression and
weight loss accompanied by im-
proved mood.
Case Report
Ms. A, a 66-year-old white woman,
was referred by another patient in
November 2006 for alcohol, depres-
sion, anxiety, panic, and chronic
